Elevance Health
ELV
910 hedge funds and large institutions have $50.8B invested in Elevance Health in 2017 Q4 according to their latest regulatory filings, with 138 funds opening new positions, 269 increasing their positions, 359 reducing their positions, and 65 closing their positions.
112% more first-time investments, than exits
New positions opened: 138 | Existing positions closed: 65
18% more capital invested
Capital invested by funds: $43.2B → $50.8B (+$7.62B)
17% more funds holding in top 10
Funds holding in top 10: 29 → 34 (+5)
8% more funds holding
Funds holding: 845 → 910 (+65)
1.46% more ownership
Funds ownership: 86.69% → 88.15% (+1.5%)
25% less repeat investments, than reductions
Existing positions increased: 269 | Existing positions reduced: 359
58% less call options, than puts
Call options by funds: $147M | Put options by funds: $352M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$515M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$354M |
| 3 |
JP Morgan Chase
New York
|
+$193M |
| 4 |
Goldman Sachs
New York
|
+$193M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$184M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIG
EdgePoint Investment Group
Toronto,
Ontario, Canada
|
-$225M |
| 2 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
-$197M |
| 3 |
TP
Third Point
New York
|
-$186M |
| 4 |
BlackRock
New York
|
-$167M |
| 5 |
GCM
Glenview Capital Management
New York
|
-$159M |
ELV Hedge Fund Activity: Q4 2017 in Review
910 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Elevance Health (ELV) for Q4 2017, worth a combined $50.8B — up 18% from $43.2B a quarter earlier.
Buyers outnumbered sellers: 138 funds opened new ELV positions and 65 closed out — a net gain of 73 holders — while 269 added to existing stakes and 359 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $515M. The largest seller was EdgePoint Investment Group, cutting an estimated $225M.
- 910 institutional investors held Elevance Health (ELV) as of Q4 2017, up from 845 in Q3 2017.
- Funds reported $50.8B of Elevance Health stock for Q4 2017, up 18% quarter-over-quarter.
- 138 funds opened new Elevance Health positions in Q4 2017 and 65 closed out, a net change of +73 holders.
- The largest Elevance Health buyer in Q4 2017 was T. Rowe Price Associates, an estimated $515M added.
- The largest Elevance Health seller in Q4 2017 was EdgePoint Investment Group, an estimated $225M sold.
Based on aggregated 13F filings for Q4 2017.